Efficacy of Artemisinin-Based and Quinine-Based Treatments for Uncomplicated Falciparum Malaria in Pregnancy

This article conducted a systematic literature review and individual patient data (IPD) meta-analysis to compare the efficacy and tolerability of different artemisinin-based or quinine-based treatments for malaria in pregnant women.

Immune Discovery Using CRISPER Cas 9 May Be Used to Treat All Cancer

According to an article in Nature Immunology researchers have used CRISPER Cas9 to discover a T-cell and its receptor that could find and kill a wide range of cancerous cells in the lab. While this discovery is the first of its kind, it is in the early stages and needs more research.  There is potential in this discovery to identify new forms of cancer treatment. 

How plague pathogens trick the immune system

Yersinia pathogens inject the enzyme YopO into the macrophages of the immune system, preventing the defense cells from digesting the plague bacteria. This article outlines a study done on the ability of YopO to change its shape and confuse the immune system, allowing for a more targeted approach to treatment and possible eradication of Yersinia.

Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States

 Treatment with BAT® [Botulism Antitoxin Heptavalent (Equine)] was associated with shorter hospital and intensive care unit stays.

Emergent BioSolutions awarded contract from HHS to support smallpox preparedness

The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.